20.98

0.87% -0.165

Catalyst Pharmaceuticals Inc (CPRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CPRX? Forum Prognose

Schlusskurs vom Vortag:

$21.15

Offen:

$21.21

24-Stunden-Volumen:

83,019

Relative Volume:

0.09

Marktkapitalisierung:

$2.55B

Einnahmen:

$434.48M

Nettoeinkommen (Verlust:

$68.15M

KGV:

20.78

EPS:

1.01

Netto-Cashflow:

$114.96M

1W Leistung:

-3.34%

1M Leistung:

-0.25%

6M Leistung:

+26.84%

1J Leistung:

+52.60%

1-Tages-Spanne:

$20.87

$21.21

1-Wochen-Bereich:

$20.44

$21.63

52-Wochen-Spanne:

$13.00

$24.27

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Firmenname

Catalyst Pharmaceuticals Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

(305) 529-2522

Adresse

355 ALHAMBRA CIRCLE, CORAL GABLES

Mitarbeiter

167

Twitter

@CatalystForRare

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

CPRX's Discussions on Twitter

Vergleichen Sie CPRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CPRX	20.98	2.55B	434.48M	68.15M	114.96M	1.01
VRTX	448.10	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	742.93	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.76	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	250.01	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.66	24.49B	3.30B	-501.07M	1.03B	11.54

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-03-14	Eingeleitet	Citigroup	Buy
2024-03-07	Eingeleitet	BofA Securities	Buy
2023-12-21	Eingeleitet	Oppenheimer	Outperform
2022-08-24	Herabstufung	ROTH Capital	Buy → Neutral
2018-09-21	Eingeleitet	Cantor Fitzgerald	Overweight
2018-09-07	Fortgesetzt	Piper Jaffray	Overweight
2016-10-05	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-04-26	Herabstufung	Piper Jaffray	Overweight → Neutral
2014-09-30	Bestätigt	ROTH Capital	Buy
2014-09-16	Bestätigt	ROTH Capital	Buy
2014-09-15	Bestätigt	H.C. Wainwright	Buy
2013-10-21	Bestätigt	Aegis Capital	Buy
2013-09-24	Eingeleitet	Maxim Group	Buy
2013-09-06	Bestätigt	Aegis Capital	Buy
2013-04-18	Eingeleitet	Aegis Capital	Buy
2012-08-27	Hochstufung	Rodman & Renshaw	Mkt Perform → Mkt Outperform
2009-10-01	Hochstufung	Merriman	Sell → Neutral
2009-05-29	Herabstufung	Hapoalim	Neutral → Underperform
2009-05-29	Herabstufung	Merriman Curhan Ford	Buy → Sell
2008-12-15	Eingeleitet	Merriman Curhan Ford	Buy
2007-11-28	Eingeleitet	Rodman & Renshaw	Mkt Outperform
2007-01-31	Eingeleitet	Stifel Nicolaus	Buy
2007-01-05	Eingeleitet	First Albany	Buy

Alle ansehen

Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten

Nov 20, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Nov 20, 2024

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 20, 2024

Nov 19, 2024

Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Nov 19, 2024

Catalyst Pharmaceuticals CEO to Present at Major Healthcare Conferences | CPRX Stock News - StockTitan

Nov 19, 2024

GSA Capital Partners LLP Makes New $625,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 19, 2024

Nov 18, 2024

Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated at Stephens - MarketBeat

Nov 18, 2024

Principal Financial Group Inc. Has $11.45 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 18, 2024

Stephens & Co. Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Overweight Recommendation - MSN

Nov 18, 2024

Nov 15, 2024

Catalyst Pharmaceuticals chairman sells shares worth $3.1 million - Investing.com

Nov 15, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Nov 15, 2024

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance

Nov 15, 2024

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Royce & Associates LP - MarketBeat

Nov 15, 2024

Nov 14, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Nov 14, 2024

Catalyst Pharmaceuticals Board Member Trades $11.51M In Company Stock - Benzinga

Nov 14, 2024

Nov 13, 2024

Catalyst Pharmaceuticals chairman sells $11.5 million in stock - Investing.com

Nov 13, 2024

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - The Manila Times

Nov 13, 2024

Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan

Nov 13, 2024

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve - Simply Wall St

Nov 13, 2024

Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point - Yahoo Finance

Nov 13, 2024

Los Angeles Capital Management LLC Buys 123,020 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 13, 2024

Nov 12, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Nov 12, 2024

Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $30.50 - MarketBeat

Nov 12, 2024

CWA Asset Management Group LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 12, 2024

Nov 11, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Nov 11, 2024

Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $36.00 at Truist Financial - MarketBeat

Nov 11, 2024

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Meritage Portfolio Management - MarketBeat

Nov 11, 2024

Nov 10, 2024